loadpatents
Patent applications and USPTO patent grants for Gundluru; Mahesh.The latest application filed is for "securinine and norsecurinine analogue compounds for the treatment of myeloid disorders".
Patent | Date |
---|---|
Securinine And Norsecurinine Analogue Compounds For The Treatment Of Myeloid Disorders App 20210220341 - Agarwal; Mukesh ;   et al. | 2021-07-22 |
Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders Grant 10,806,723 - Agarwal , et al. October 20, 2 | 2020-10-20 |
Securinine And Norsecurinine Analogue Compounds For The Treatment Of Myeloid Disorders App 20190083472 - Agarwal; Mukesh ;   et al. | 2019-03-21 |
HDMX inhibitors and their use for cancer treatment Grant 10,183,912 - Wald , et al. Ja | 2019-01-22 |
Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders Grant 10,130,616 - Agarwal , et al. November 20, 2 | 2018-11-20 |
Novel Hdmx Inhibitors And Their Use For Cancer Treatment App 20170022166 - Wald; David ;   et al. | 2017-01-26 |
Securinine And Norsecurinine Analogue Compounds For The Treatment Of Myeloid Disorders App 20160263089 - Agarwal; Mukesh ;   et al. | 2016-09-15 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.